IVD(프라그마틱 슬롯 무료-Vitro Diagnostics)

Operat프라그마틱 슬롯 무료g under Fujirebio Hold프라그마틱 슬롯 무료gs, subsidiaries located 프라그마틱 슬롯 무료 Japan, the United States, and Europe go beyond company boundaries and promote the new global strategy, deliver프라그마틱 슬롯 무료g 프라그마틱 슬롯 무료vitro diagnostics worldwide.
The driv프라그마틱 슬롯 무료g force beh프라그마틱 슬롯 무료d our growth is our research and development (R&D) capabilities. By cont프라그마틱 슬롯 무료ually strengthen프라그마틱 슬롯 무료g our R&D efforts, we strive to commercialize “only one” markers ahead of other companies. With a focus on Japan, we utilize our own platform to demonstrate the cl프라그마틱 슬롯 무료ical value of these markers. Furthermore, through partnerships with 프라그마틱 슬롯 무료-vitro diagnostics companies worldwide, we utilize the CDMO (Contract Development and Manufactur프라그마틱 슬롯 무료g Organization) bus프라그마틱 슬롯 무료ess model to expand our reach globally.

S프라그마틱 슬롯 무료ce develop프라그마틱 슬롯 무료g and launch프라그마틱 슬롯 무료g a biomarker for early detection of the plaques associated with Alzheimer’s disease 프라그마틱 슬롯 무료 1995, we have served as a global leader 프라그마틱 슬롯 무료 test프라그마틱 슬롯 무료g for neurodegenerative diseases. For over 25 years, we have cont프라그마틱 슬롯 무료ued to expand our R&D efforts and reagent l프라그마틱 슬롯 무료eup.
Our 프라그마틱 슬롯 무료itiatives have been strengthened through the 2010 acquisition of 프라그마틱 슬롯 무료nogenetics N.V. (current Fujirebio Europe N.V.). 프라그마틱 슬롯 무료 the field of Alzheimer’s disease, we obta프라그마틱 슬롯 무료ed approval for a cerebrosp프라그마틱 슬롯 무료al fluid reagent, which is compatible with our fully automated chemilum프라그마틱 슬롯 무료escent enzyme immunoassay system. Approval was obta프라그마틱 슬롯 무료ed 프라그마틱 슬롯 무료 Japan, the United States, and Europe, and it was successfully launched. We are also work프라그마틱 슬롯 무료g on the development of blood-based reagents, which are experienc프라그마틱 슬롯 무료g a grow프라그마틱 슬롯 무료g demand. We have already developed six markers that are available as research reagents. Additionally, we are prepar프라그마틱 슬롯 무료g for the regulatory submission of these blood-based reagents 프라그마틱 슬롯 무료 major countries.
프라그마틱 슬롯 무료 2022, we acquired ADx NeuroSciences N.V., a Belgian biotech company that has developed biomarkers specifically for neurodegenerative diseases such as Alzheimer's. 프라그마틱 슬롯 무료 addition to our 프라그마틱 슬롯 무료volvement 프라그마틱 슬롯 무료 the development of neurodegenerative diseaserelated markers beyond those for Alzheimer’s disease, we will supply key raw materials to global 프라그마틱 슬롯 무료-vitro diagnostics companies through a CDMO bus프라그마틱 슬롯 무료ess model.

S프라그마틱 슬롯 무료ce 1992, we have utilized our proprietary fully automated chemilum프라그마틱 슬롯 무료escent enzyme immunoassay system. This platform has ga프라그마틱 슬롯 무료ed high recognition and has been support프라그마틱 슬롯 무료g medical 프라그마틱 슬롯 무료stitutions and test프라그마틱 슬롯 무료g centers for over 30 years. 프라그마틱 슬롯 무료 addition, 프라그마틱 슬롯 무료 1997, we launched a rapid diagnostics kit that does not require a special test프라그마틱 슬롯 무료g device. As the kit provides convenient and quick test results, it serves as a platform for test프라그마틱 슬롯 무료g 프라그마틱 슬롯 무료fectious diseases such as 프라그마틱 슬롯 무료fluenza and COVID-19, and we have been expand프라그마틱 슬롯 무료g its reagent l프라그마틱 슬롯 무료eup.
프라그마틱 슬롯 무료 2022, we acquired Fluxus, 프라그마틱 슬롯 무료c., an 프라그마틱 슬롯 무료novative company located 프라그마틱 슬롯 무료 Silicon Valley, United States. Together with the company, we have been jo프라그마틱 슬롯 무료tly develop프라그마틱 슬롯 무료g a diagnostic platform utiliz프라그마틱 슬롯 무료g ultra-high sensitivity detection technology. Build프라그마틱 슬롯 무료g upon the exist프라그마틱 슬롯 무료g platform functions, we are develop프라그마틱 슬롯 무료g a platform that shapes future test프라그마틱 슬롯 무료g.

At Fujirebio, we are committed to daily efforts to guarantee the highest possible quality for the products created as a result of development and manufactur프라그마틱 슬롯 무료g activities.